Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic MalignanciesNina Shah, Krina K. Patel, Mitchell S. Cairo et al.|Future Oncology|2021Cited by 21
Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 StudyCameron J. Turtle, Nina Shah, Krina K. Patel et al.|Blood|2021Cited by 6
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Blood|2021Cited by 4
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Regular and Young Investigator Award Abstracts|2020Cited by 3
Defining the optimal timing of adjuvant therapy for resected pancreatic cancer: A statewide cancer registry analysis.Hayder Saeed, Ching‐Wei D. Tzeng, Dima Hnoosh et al.|Journal of Clinical Oncology|2015Cited by 0